Previous research has indicated that bleeding occurrences during nintedanib therapy are not associated with thrombocytopenia (13), and the drug’s mechanism of action involving PDGFR inhibition may account for the observed decrease in platelet counts (14). This evidence concerns the gene PDGFRB and Thrombocytopenia.